LOG IN
SIGN UP
MARKET
CSBR
CSBR
Champions Oncolo
NASDAQ
Real-time Quotes | Nasdaq Last Sale
7.76
-0.02
-0.26%
Opening 09:48 07/05 EDT
OPEN
7.77
PREV CLOSE
7.78
HIGH
7.77
LOW
7.76
VOLUME
233
TURNOVER
1.80K
52 WEEK HIGH
11.00
52 WEEK LOW
6.81
MARKET CAP
104.93M
P/E (TTM)
256.95
1D
5D
1M
3M
1Y
5Y
Investors in Champions Oncology (NASDAQ:CSBR) have made a impressive return of 197% over the past five years
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Simply Wall St. · 06/13 10:30
Champions Oncology Announces A Partnership With Cyclica To Develop Small Molecule Therapeutics; Terms Not Disclosed
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc.
Benzinga · 05/31 12:34
Champions Oncology to Collaborate With Cyclica to Jointly Develop Small Molecule Therapeutics
MT Newswires · 05/31 11:15
Champions Oncology, Inc.'s (NASDAQ:CSBR) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Champions Oncology (NASDAQ:CSBR) has had a rough month with its share price down 7.0%. However, stock prices are...
Simply Wall St. · 05/02 17:16
Here's How Much You Would Have Made Owning Champions Oncology Stock In The Last 5 Years
Champions Oncology (NASDAQ:CSBR) has outperformed the market over the past 5 years by 7.88% on an annualized basis.
Benzinga · 03/21 16:01
Champions Oncology Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q3, Champions Oncology (NASDAQ:CSBR) earned $787.00 thousand, a 184.12% increase from the preceding quarter. Champions Oncology also posted a total of $13.19 million in sales, a 11.94% increase since Q2.
Benzinga · 03/16 15:04
Champions Oncology Non-GAAP EPS of $0.07, revenue of $13.2M
Champions Oncology press release (NASDAQ:CSBR): Q3 Non-GAAP EPS of $0.07. Revenue of $13.2M.
Seekingalpha · 03/15 21:02
Champions Oncology Fiscal Q3 EPS Declines, Revenue Increases
MT Newswires · 03/15 17:05
No Data
Learn about the latest financial forecast of CSBR. Analyze the recent business situations of Champions Oncolo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 3 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CSBR stock price target is 14.67 with a high estimate of 17.00 and a low estimate of 13.00.
Current 7.76
EPS
Actual
Estimate
-0.020.000.020.04
- 0
Institutional Holdings
Institutions: 53
Institutional Holdings: 9.20M
% Owned: 68.07%
Shares Outstanding: 13.52M
TypeInstitutionsShares
Increased
8
22.26K
New
1
16.08K
Decreased
8
48.34K
Sold Out
2
1.15K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.69%
Pharmaceuticals & Medical Research
-0.48%
Key Executives
Non-Executive Chairman/Independent Director
Joel Ackerman
Chief Executive Officer/Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Director/Independent Director
David Sidransky
Director
Robert Brainin
Independent Director
Philip Breitfeld
Independent Director
Daniel Mendelson
Independent Director
Scott Tobin
No Data
No Data
About CSBR
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Webull offers kinds of Champions Oncology Inc stock information, including NASDAQ:CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.